Generex's oral insulin submitted for approval in Syria
This article was originally published in Scrip
Executive Summary
Generex Biotechnologyhas submitted a marketing application in Syria for its oral insulin product, Generex Oral-lyn, and expects approval before the end of next year. Generex's product uses its RapidMist device to deliver a liquid spray of insulin to the lining of the mouth. The product is available in Ecuador, and has been approved for sale in India. Phase III clinical trials are under way in the US and elsewhere.